Shots:
- Qiagen reports the launch of the Access Anti-SARS-CoV-2 Total test that runs on a portable device and provides accurate results on Total Ig Abs (IgA, IgM, IgG) in 10mins. The device can process up to 8 samples simultaneously or up to 32 tests/hour
- The test was developed in collaboration with Ellume, following the US FDA’s EUA submission. The companies plan to launch it in the US in Aug’2020 while anticipates the CE-IVD marking in the EU with the initiation of commercialization in other markets in coming weeks
- The test is performed on eHub & eStick system provides rapid qualitative serological in-vitro detection of total antibodies to SARS-CoV-2 in plasma & serum and has demonstrated 100% sensitivity & specificity
Click here to read full press release/ article | Ref: Qiagen | Image: Fierce Biotech
Related News: Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations and Strains
